Figure S1. Immunohistochemical analysis showing expression of ADAM12 in 63 pairs of human GC and adjacent non-tumor tissues in a microarray. The odd columns (columns A, C, E, G, I, K, M) represent tumor tissues and the even columns (columns B, D, F, H, J, L, N) represent corresponding adjacent non-tumor tissues. ADAM12, a disintegrin and metallopro-tease 12; GC, gastric cancer.

Figure S2. The Kaplan-Meier survival curve of DFS for the high and low ADAM12 expression groups based on the IHC score from a tissue microarray. DFS, disease-free survival; ADAM12, a disintegrin and metalloprotease 12; GC, gastric cancer; IHC, immunohistochemistry.

Figure S3. hsa-miR-29c-3p and has-miR-135a-5p significantly inhibit the expression of ADAM12 in GC. (A) The levels of hsa-miR-29c-3p and has-miR-135a-5p were determined in HGC27 cells which transfected with the miR-NC and corresponding miRNA mimics by RT-qPCR (***P<0.001, ****P<0.0001). (B) The protein levels of ADAM12 were determined in the hsa-miR-29c-3p and has-miR-135a-5p overexpressed HGC27 cells via western blot assay. ADAM12, a disintegrin and metalloprotease; GC, gastric cancer.

Figure S4. Knockdown and overexpression efficiency of ADAM12 in HGC27 and AGS cells, respectively. ADAM12, a disintegrin and metalloprotease; GC, gastric cancer.